Note

BREAKING: Sinovac's Covid vaccine triggers quick immune response after Pfizer’s 90% efficacy

Verified Official
· Views 279

According to the preliminary trial results released on Wednesday, Sinovac Biotech’s experimental COVID-19 vaccine, CoronaVac, induced a quick immune response although its effectiveness cannot be determined as it is in the early to mid-stage clinical trials, per Reuters.

Sinovac is currently running three Phase III trials in Indonesia, Brazil and Turkey.

Additional details

“Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval.”

“We believe that this makes the vaccine suitable for emergency use during the pandemic.”

Over the past week, American pharma giants Pfizer and Moderna have shown that their covid vaccine has over 90% effective based on interim data from large, late-stage trials.

Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.

FOLLOWME Trading Community Website: https://www.followme.com

If you like, reward to support.
avatar

Hot

No comment on record. Start new comment.